About Vivos Inc
- Industry: Health Care
- Exchange: OTC MARKETS
- Country: US
- Website: https://www.radiogel.com/
Frequently Asked Questions
What is the 52-week range for RDGL?
The 52-week high is $0.1244 and the 52-week low is $0.04.
What is the P/E ratio for RDGL?
The P/E ratio data is currently unavailable.
What is the dividend yield for RDGL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -154.94%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3633.54%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 18.86.
Latest RDGL News
Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate
Vivos Therapeutics is implementing a restructuring plan targeting $3. 6 million in annual savings while expanding several revenue initiatives that management believes could support cash flow positivity by late 2026 or early 2027.
Vivos Therapeutics Announces Material Debt Reduction
Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced t
Vivos Inc. Peer-Reviewed PrecisionGel Publication Strengthens Scientific Case for Drug Delivery Platform
The Elsevier journal publication characterizes PrecisionGel’s biomolecular release properties, adding peer-reviewed support for Vivos Inc. ’s (USOTC:RDGL) clinical, regulatory and potential licensing efforts.
Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology
Kennewick, WA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company developing Precision Radionuclide Therapy™ (PRnT) for cancerous tumors in humans and animals, today announced the peer-reviewed publication of a paper describing the PrecisionGel™ thermogel polymer platform in the Journal of Drug Delivery Science and Technology. PrecisionGel™ is the polymer carrier component of both IsoPet® and RadioGel® and is also available independently to pharmaceutical and b
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Korenko Michael K | +200,000 | $0.498 | $99,600 |
| 2026-09-16 | Weeks Brad Allan | +25,550 | $0.0482 | $1,232 |
| 2026-08-10 | Weeks Brad Allan | +50,000 | $0.0548 | $2,740 |
| 2026-08-10 | Korenko Michael K | +150,000 | $0.0531 | $7,965 |
| 2026-07-22 | Weeks Brad Allan | +32,000 | $0.05 | $1,600 |
| 2026-07-21 | Weeks Brad Allan | +60,000 | $0.05 | $3,000 |
| 2026-07-15 | Korenko Michael K | +200,000 | $0.0571 | $11,420 |
| 2026-07-10 | Weeks Brad Allan | +12,000 | $0.08 | $960 |
| 2026-07-10 | Weeks Brad Allan | +12,000 | $0.08 | $960 |
| 2026-07-09 | Weeks Brad Allan | +48,000 | $0.08 | $3,840 |
| 2026-07-09 | Weeks Brad Allan | +48,000 | $0.08 | $3,840 |
| 2026-06-30 | Weeks Brad Allan | +147,159 | - | - |
| 2026-05-11 | Korenko Michael K | +150,000 | $0.0618 | $9,270 |
| 2026-03-31 | Weeks Brad Allan | +100,111 | - | - |
| 2025-12-31 | Korenko Michael K | +200,000 | $0.0646 | $12,920 |
| 2025-12-02 | Korenko Michael K | +100,000 | $0.0722 | $7,220 |
| 2025-11-20 | Korenko Michael K | +100,000 | $0.0622 | $6,220 |